HAX

HAX is a venture capital program focused on accelerating hardware startups through its comprehensive support and resources. Founded in 2012 and headquartered in Newark, New Jersey, HAX operates in two key locations, San Francisco and Shenzhen, providing founders with an environment conducive to rapid prototyping and iterative development. The program emphasizes the importance of launching both B2C and B2B hardware startups, guiding them through critical phases such as business development, fundraising, and market entry. HAX accepts teams that demonstrate strong potential for scaling their ventures and solving significant technological challenges. Through a structured curriculum, entrepreneurs refine their product-market fit and business strategies while benefiting from a robust network of mentors and industry connections. HAX maintains an ongoing relationship with participating startups to support their growth beyond the initial program, ensuring they have the necessary resources and partnerships to succeed in the competitive marketplace.

Andrew Gollach

Principal

Duncan Turner

Managing Director

Past deals in Mental Health

Samphire Neuroscience

Seed Round in 2024
Samphire Neuroscience, founded in 2021 and based in London, specializes in women's health through innovative neurotechnology solutions. The company develops a headband device that utilizes non-invasive electrical neuromodulation to target specific areas of the brain. This approach aims to alleviate symptoms commonly associated with the menstrual cycle, such as pain, fatigue, and mood fluctuations. By focusing on enhancing women's health and lifestyles, Samphire Neuroscience strives to provide effective relief for those affected by these challenges.

Flow Neuroscience

Convertible Note in 2024
Flow Neuroscience, established in 2011 and based in Malmö, Sweden, specializes in developing and manufacturing a wearable device and accompanying mobile application for medication-free treatment of depression. The company's core product is a transcranial direct current stimulation (tDCS) headset that targets the left frontal lobe, an area of the brain often associated with depression. This non-invasive treatment is complemented by a personalized mobile app that encourages users to adopt healthier daily routines, such as regular exercise and sleep patterns, to help alleviate depressive symptoms. Flow Neuroscience aims to make this innovative, affordable treatment accessible to the public, challenging the dominance of pharmaceuticals in mental health care.

Lief Therapeutics

Seed Round in 2024
Lief Therapeutics is a medical device company based in San Francisco, California, focused on enhancing at-home care for individuals dealing with post-traumatic stress disorder, depression, and anxiety. The company has developed a discreet bio-sensing patch that accurately measures heart rate and breath, allowing users to manage their natural stress response through vibratory biofeedback exercises. This wearable device helps users monitor their behaviors, emotions, and thoughts in real-time, fostering mindfulness and control throughout the day. Additionally, it supports clinicians by tracking patient progress, facilitating in-session training, and scheduling psychological assessments. Lief Therapeutics also offers the Lief Health Score application, which records thoughts, emotions, and sensations, enabling users to track daily progress and engage in tailored exercises. Founded in 2014, the company sells its products online, aiming to empower individuals in their mental health journeys.

Samphire Neuroscience

Pre Seed Round in 2024
Samphire Neuroscience, founded in 2021 and based in London, specializes in women's health through innovative neurotechnology solutions. The company develops a headband device that utilizes non-invasive electrical neuromodulation to target specific areas of the brain. This approach aims to alleviate symptoms commonly associated with the menstrual cycle, such as pain, fatigue, and mood fluctuations. By focusing on enhancing women's health and lifestyles, Samphire Neuroscience strives to provide effective relief for those affected by these challenges.

Samphire Neuroscience

Convertible Note in 2023
Samphire Neuroscience, founded in 2021 and based in London, specializes in women's health through innovative neurotechnology solutions. The company develops a headband device that utilizes non-invasive electrical neuromodulation to target specific areas of the brain. This approach aims to alleviate symptoms commonly associated with the menstrual cycle, such as pain, fatigue, and mood fluctuations. By focusing on enhancing women's health and lifestyles, Samphire Neuroscience strives to provide effective relief for those affected by these challenges.

Lief Therapeutics

Convertible Note in 2022
Lief Therapeutics is a medical device company based in San Francisco, California, focused on enhancing at-home care for individuals dealing with post-traumatic stress disorder, depression, and anxiety. The company has developed a discreet bio-sensing patch that accurately measures heart rate and breath, allowing users to manage their natural stress response through vibratory biofeedback exercises. This wearable device helps users monitor their behaviors, emotions, and thoughts in real-time, fostering mindfulness and control throughout the day. Additionally, it supports clinicians by tracking patient progress, facilitating in-session training, and scheduling psychological assessments. Lief Therapeutics also offers the Lief Health Score application, which records thoughts, emotions, and sensations, enabling users to track daily progress and engage in tailored exercises. Founded in 2014, the company sells its products online, aiming to empower individuals in their mental health journeys.

Samphire Neuroscience

Seed Round in 2022
Samphire Neuroscience, founded in 2021 and based in London, specializes in women's health through innovative neurotechnology solutions. The company develops a headband device that utilizes non-invasive electrical neuromodulation to target specific areas of the brain. This approach aims to alleviate symptoms commonly associated with the menstrual cycle, such as pain, fatigue, and mood fluctuations. By focusing on enhancing women's health and lifestyles, Samphire Neuroscience strives to provide effective relief for those affected by these challenges.

Samphire Neuroscience

Seed Round in 2021
Samphire Neuroscience, founded in 2021 and based in London, specializes in women's health through innovative neurotechnology solutions. The company develops a headband device that utilizes non-invasive electrical neuromodulation to target specific areas of the brain. This approach aims to alleviate symptoms commonly associated with the menstrual cycle, such as pain, fatigue, and mood fluctuations. By focusing on enhancing women's health and lifestyles, Samphire Neuroscience strives to provide effective relief for those affected by these challenges.

Flow Neuroscience

Series A in 2021
Flow Neuroscience, established in 2011 and based in Malmö, Sweden, specializes in developing and manufacturing a wearable device and accompanying mobile application for medication-free treatment of depression. The company's core product is a transcranial direct current stimulation (tDCS) headset that targets the left frontal lobe, an area of the brain often associated with depression. This non-invasive treatment is complemented by a personalized mobile app that encourages users to adopt healthier daily routines, such as regular exercise and sleep patterns, to help alleviate depressive symptoms. Flow Neuroscience aims to make this innovative, affordable treatment accessible to the public, challenging the dominance of pharmaceuticals in mental health care.

Flow Neuroscience

Convertible Note in 2020
Flow Neuroscience, established in 2011 and based in Malmö, Sweden, specializes in developing and manufacturing a wearable device and accompanying mobile application for medication-free treatment of depression. The company's core product is a transcranial direct current stimulation (tDCS) headset that targets the left frontal lobe, an area of the brain often associated with depression. This non-invasive treatment is complemented by a personalized mobile app that encourages users to adopt healthier daily routines, such as regular exercise and sleep patterns, to help alleviate depressive symptoms. Flow Neuroscience aims to make this innovative, affordable treatment accessible to the public, challenging the dominance of pharmaceuticals in mental health care.

Flow Neuroscience

Seed Round in 2018
Flow Neuroscience, established in 2011 and based in Malmö, Sweden, specializes in developing and manufacturing a wearable device and accompanying mobile application for medication-free treatment of depression. The company's core product is a transcranial direct current stimulation (tDCS) headset that targets the left frontal lobe, an area of the brain often associated with depression. This non-invasive treatment is complemented by a personalized mobile app that encourages users to adopt healthier daily routines, such as regular exercise and sleep patterns, to help alleviate depressive symptoms. Flow Neuroscience aims to make this innovative, affordable treatment accessible to the public, challenging the dominance of pharmaceuticals in mental health care.

BrainBot

Seed Round in 2015
BrainBot is a company focused on developing innovative brain sensing applications aimed at improving overall health and well-being. Founded with the inspiration of measuring the brainwaves of meditating monks in the Himalayan mountains, the company leverages neuroscience technology to help users enhance resilience against anxiety, depression, chronic pain, addiction, and eating disorders. Through their applications, BrainBot enables individuals to decrease stress and improve cardiovascular health by promoting effective meditation practices. The company's commitment to integrating technology with mental wellness reflects its vision to facilitate better health outcomes for users.

Lief Therapeutics

Seed Round in 2015
Lief Therapeutics is a medical device company based in San Francisco, California, focused on enhancing at-home care for individuals dealing with post-traumatic stress disorder, depression, and anxiety. The company has developed a discreet bio-sensing patch that accurately measures heart rate and breath, allowing users to manage their natural stress response through vibratory biofeedback exercises. This wearable device helps users monitor their behaviors, emotions, and thoughts in real-time, fostering mindfulness and control throughout the day. Additionally, it supports clinicians by tracking patient progress, facilitating in-session training, and scheduling psychological assessments. Lief Therapeutics also offers the Lief Health Score application, which records thoughts, emotions, and sensations, enabling users to track daily progress and engage in tailored exercises. Founded in 2014, the company sells its products online, aiming to empower individuals in their mental health journeys.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.